Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion

被引：0

作者：

F C Lowe

J Batista

R Berges

E Chartier-Kastler

G Conti

F Desgrandchamps

K Dreikorn

M O'Leary

M Perez

M Speakman

J Trachtenberg

A Tubaro

B Meesen

L Smets

H Stoevelaar

机构：

[1] St Luke's-Roosevelt Hospital Center,

[2] Fundacion Puigvert/ CM Teknon,undefined

[3] PAN-Klinik am Neumarkt,undefined

[4] GH Pitié-Salpétrière,undefined

[5] Ospedale S. Anna,undefined

[6] CHU Saint Louis,undefined

[7] Zentralkrankenhaus St-Juergenstrasse,undefined

[8] Brigham & Women's Hospital,undefined

[9] Medical Sciences University of the São Paulo Santa Casa Hospital,undefined

[10] Taunton & Somerset Hospital,undefined

[11] University of Toronto & Princess Margaret Hospital,undefined

[12] La Sapienza University,undefined

[13] Sant'Andrea Hospital,undefined

[14] Ismar Healthcare,undefined

[15] Erasmus University Medical Center,undefined

来源：

Prostate Cancer and Prostatic Diseases | 2005年 / 8卷

关键词：

lower urinary tract symptoms; benign prostatic hyperplasia; disease progression; risk factors;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Disease progression has become an important issue for the management of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). Although several risk factors have been identified, no specific patient risk profiles have been established that can be useful in the day-to-day management of LUTS/BPH. In this study, an international panel of urologists developed a risk classification based on the attribution of a risk score to 243 unique patient profiles. From the perspective of clinical decision making, it was concluded that postvoid residual, symptom severity and maximum flow rate are the most relevant determinants of the risk of disease progression.

引用

页码：206 / 209

页数：3

共 18 条

[1]

Jacobsen SJ(1997)Natural history of prostatism: risk factors for acute urinary retention J Urol 158 481-487

[2]

McConnell JD(1998)The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group N Engl J Med 338 557-563

[3]

Roehrborn CG(1999)Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group Urology 53 473-480

[4]

McConnell JD(2003)Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients J Urol 169 332-365

[5]

Roehrborn CG(2003)PSA is a significant predictor of objective parameters in men at risk of BPH progression J Urol 169 364-2398

[6]

Boyle P(2003)The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2387-12

[7]

Nickel JC(2003)Identifying patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression Eur Urol Suppl 2 6-333

[8]

McConnell JD(2003)Baseline symptoms, uroflow, and post-void residual urine as predictors of BPH clinical progression in the medically treated arms of the MTOPS trial J Urol 169 332-63

[9]

Jimenez-Cruz F(2004)Integrating risk profiles in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia. A systematic analysis of expert opinion Eur Urol Suppl 3 61-496

[10]

Kaplan SA(1986)A method for the detailed assessment of the appropriateness of medical technologies Int J Technol Assess Health Care 2 53-35

← 1 2 →